Hengrui Medicine (01276.HK): The drug application for the new indication of Adcetris injection has been accepted by the National Medical Products Administration.

Wisdom Finance and Economics APP news, Hengrui Medicine (01276.HK) announced that recently, the company's subsidiary Shanghai Shengdi Pharmaceutical Co., Ltd. received the "Acceptance Notice" issued by the National Medical Products Administration. The company's drug Adelbeil Monoclonal Antibody Injection has obtained approval for the listing application of a new indication by the National Medical Products Administration.